GLP-1 Market
LLY $1306.69 ▲ +2.8% NVO $39.43 ▲ +0.9% PFE $30.42 ▲ +1.9% VKTX $25.83 ▼ -2.1% KLRA $13.27 ▲ +2.7% GPCR $21.93 ▼ -0.4% RHHBY $59.62 ▲ +0.9%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Evuzamitide

Company
Lorena Saelices
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 23, 2026

Find a Clinical Trial Near Me

See recruiting studies for Evuzamitide and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05758493

    Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis

    Not yet reported Oregon Health and Science University 150 participants Est. completion 2028-03-10 1 site Stand-alone
    Other conditions: Amyloidosis, Transthyretin Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT05951816

    A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

    Not yet reported University of Tennessee Graduate School of Medicine 31 participants Est. completion 2027-06 1 site
    Other conditions: Systemic Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06974877

    Repeat PET/CT Imaging in People With CAPS and Anakinra-Induced Amyloidosis Using an Amyloid-Reactive Peptide to Measure Changes in Organ-Specific Amyloid Load

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 30 participants Est. completion 2032-01-31 1 site
    Other conditions: Cryopyrin-Associated Periodic Syndromes, Amyloidosis
    View official trial listing →
  • Completed NCT NCT05635045

    Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR

    Not yet reported Columbia University 10 participants Est. completion 2024-06-12 1 site
    Other conditions: Transthyretin Amyloidosis
    View official trial listing →
  • Completed NCT NCT05968846

    Repeat PET/CT Imaging of Patients With Amyloid 124I-AT-01 to Measure Changes in Organ-specific Amyloid Load

    Not yet reported University of Tennessee Graduate School of Medicine 19 participants Est. completion 2023-09-01 1 site Stand-alone
    Other conditions: Systemic Amyloidosis
    View official trial listing →
  • Completed NCT NCT06788535

    REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis

    Not yet reported Sharmila Dorbala 204 participants Est. completion 2026-04-09 20 sites Stand-alone
    Other conditions: Cardiac Amyloidosis
    View official trial listing →
  • Enrolling by invitation NCT NCT06907849

    124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome

    Not yet reported University of Tennessee Graduate School of Medicine 40 participants Est. completion 2027-05 1 site Stand-alone
    Other conditions: Lumbar Spinal Stenosis, Carpal Tunnel Syndrome (CTS), Cardiac Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07538518

    PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels

    Lorena Saelices 25 participants Est. completion 2028-04-01 3 sites
    Other conditions: Amyloidogenic Transthyretin (ATTR) Amyloidosis, Cardiac Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07591038

    PET/CT Imaging in Carriers of TTR Mutations

    University of Texas Southwestern Medical Center 80 participants Est. completion 2030-06-30 1 site
    Other conditions: ATTR, ATTR Gene Mutation, Cardiomyopathy, Transthyretin Mediated Amyloidosis (ATTR)
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.